| Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma BE Stubbe, SD Henriksen, AC Larsen, HB Krarup, MN Johansen, ... Cancers 13 (22), 5517, 2021 | 8 | 2021 |
| Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma – An external validation study SD Henriksen, BE Stubbe, PH Madsen, Madsen, JS Johansen, ... Pancreatology 21 (6), 1081-1091, 2021 | 5 | 2021 |
| Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma BE Stubbe, PH Madsen, AC Larsen, HB Krarup, IS Pedersen, CP Hansen, ... Pancreatology 23 (5), 512-521, 2023 | | 2023 |
| Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma BE Stubbe, AC Larsen, PH Madsen, HB Krarup, IS Pedersen, ... Frontiers in Oncology 13, 1211292, 2023 | | 2023 |
| Abstract B047: Promoter hypermethylation of SFRP1 as a prognostic and predictive blood-based biomarker in patients with stage IV pancreatic ductal adenocarcinoma BE Stubbe, SD Henriksen, PH Madsen, AC Larsen, HB Krarup, ... Cancer Research 82 (22_Supplement), B047-B047, 2022 | | 2022 |
| SFRP1 Promoter Hypermethylation as a Predictor of Survival and Gemcitabine Efficiency in Patients with Stage IV Pancreatic Adenocarcinoma B Stubbe, SD Henriksen, PH Madsen, AC Larsen, HB Krarup, ... | | 2021 |
| Validation of Updated Diagnostic Criteria: IDH-Wildtype Diffuse Astrocytoma with Molecular Features of Glioblastoma BE Stubbe, MH Eskesen, CA Haslund, A Carus, MS Ettrup, AM Delekta, ... | | 2021 |
| Søvnmangel og depression hos teenagere MM Holt, RH Knudsen, LF Madsen, AH Simoni, BE Stubbe, ... | | |
Inge Søkilde PedersenAalborg UniversityhospitalVerified email at rn.dk
